ClinicalTrials.gg
RecruitingNCT07183592TANDOORIUpdated May 13, 2026

Impact of Infusion Line Change Frequency on Infectious Complications Related to Central Venous Catheters in the ICU - A Randomized Controlled Trial

An interventional study of 7-day Infusion set replacement and 4-day infusion set replacement in Intensive Care (ICU), Central Venous Catheter Related Infections and Critical Care Nursing, sponsored by University Hospital, Angers. Recruiting at 27 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by University Hospital, Angers · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,830
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Catheter-Related Infections with a site in France — 4 open to participants now, 4 under way, none of them phase 3. Catheter-Related Infections · France.

Planned enrollment
Largest of 10
2,830 · median 300
Started
2026
with 3 others
No phase
7 of 16
2 open now
Registered
13th of 16
by date

Among the 16 studies in Catheter-Related Infections with a site in France, this one has the largest planned enrollment of the 10 interventional ones that give a count, is one of 4 that started in 2026, is one of 7 with no phase, and was the 13th registered.

Catheter-Related Infections

113 studies on the registry are indexed under Catheter-Related Infections; 19 are open to participants now.

Browse Catheter-Related Infections studies →

Open to participants now

4 of the 16 studies in Catheter-Related Infections with a site in France are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 10 Catheter-Related Infections studies recruiting now, 9 (90%) set no upper age limit and 1 (10%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Catheter-Related Infections with a site in France, or all of them as a file.
02

Study summary

In the intensive care unit, patients' care and secure drugs administration require a central venous catheter. These invasive devices can lead to complications, particularly infections. Most preventive recommendations focus on catheter insertion, line handling, and dressings. Few recommendations adress catheter dwell time, which is certainly the main source of infection. Part of the prevention strategy is the regular and systematic replacement of infusion sets , as they may become contaminated during use, mainly through the hands of healthcare professionals. Prolonged use increases the risk of infection. Infusion lines changes involve disconnecting the old sets, discarding infusion devices containing drug residues, and replacing them with new sterile devices.

Current international guidelines recommend replacing these sets every 4 days, and the Center for Disease Control and Prevention recommends not exceeding 7 days. Replacing these devices requires the time of qualified nurses, numerous sterile medical devices, and medications. In addition to the intended effect on infection prevention, the procedure has impacts on workload and costs.

The objective of the study is to demonstrate that changing infusion set every 7 days does not increase the rate of central venous catheters related infections compared with changing infusion set every 4 days.

03

Conditions studied

  • Intensive Care (ICU)
  • Central Venous Catheter Related Infections
  • Critical Care Nursing
  • Catheter-associated Bloodstream Infections (CLABSI)
  • Nursing Workload
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient
  • Any ICU patient with a central venous catheter (inserted by venipuncture) in place for less than 72 hours and with an expected dwell time of at least 7 days
  • Patient affiliated with or covered by a social security system
  • Patient who has given verbal consent or written consent from a third party or in the event that the patient is unable to give consent.

Exclusion criteria

Exclusion Criteria

  • Patient with a documented bloodstream infection at the time of inclusion
  • Patient whose central venous catheter has been in place for more than 72 hours
  • Patient with suspected catheter-related infection
  • Patient whose study catheter was inserted using a guidewire exchange
  • Patient previously enrolled in the study during the same ICU stay
  • Patient whose condition, according to the clinician, does not allow safe placement of a central venous catheter, such as:

    • Allergy to catheter material
    • Confirmed deep vein thrombosis at the time of insertion
    • Inflammatory skin disorder at the insertion site
  • Patient admitted for extensive burns
  • Inadequate understanding of the French language
  • Pregnant, breastfeeding, or postpartum woman
  • Person deprived of liberty by judicial or administrative decision
  • Person receiving involuntary psychiatric care
  • Person under legal guardianship or other legal protection measure
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,830 participants (estimated)

Study arms

  • Experimental
    7-day infusion set replacement

    Infusion sets connected to the central venous catheter will be replaced every 7 days.

    Procedure: 7-day Infusion set replacement

  • Active comparator
    4-day infusion set replacement

    Infusion sets connected to the central venous catheter will be replaced every 4 days.

    Procedure: 4-day infusion set replacement

Interventions

  • Procedure7-day Infusion set replacement

    7-day infusion set replacement (Experimental arm) In this group, the infusion sets (the tubes and connectors used to deliver medications through the central venous catheter) will be changed once a week, every 7 days. During each replacement, all sets will be disconnected and replaced with new sterile ones.

  • Procedure4-day infusion set replacement

    4-day infusion set replacement (Active comparator arm) In this group, the infusion sets will be changed every 4 days, which reflects the most common international recommendation. The procedure is the same: all sets connected to the central venous catheter will be replaced with new sterile ones. This strategy represents the current standard of care and will serve as the comparison for the 7-day approach.

06

What researchers measure

Primary outcomes

  1. Rate (%) of patients with with a central venous catheter-related infectious complication

    Infectious complications include: 1. Catheter-related infections (CRI) defined as: * A positive catheter culture, with quantitative culture ≥10³ CFU/ml (Brun-Buisson technique) or, if not available, a semi-quantitative culture \>15 CFU (Maki technique), and purulence at the catheter insertion site or tunnelitis. Or * A positive catheter culture, with quantitative culture ≥10³ CFU/ml (or semi-quantitative culture \>15 CFU), and complete or partial regression of systemic signs of infection within 48 hours after catheter removal. 2. Catheter-related bloodstream infections (bacteremia or fungemia) defined as: * The occurrence of bacteremia (or fungemia) within 48 hours before or after catheter removal (or suspected catheter-related infection if the catheter is not immediately removed), And * Either a positive culture with the same microorganism from the insertion site or catheter, with ≥10³ CFU/ml (Brun-Buisson technique) or, if not available, a semi-quantitative culture

    Time frame: From central venous catheter insertion until 48 hours after catheter removal during the ICU stay (censored at 90 days).

Secondary outcomes

  1. Central line-associated bloodstream infection (CLABSI)

    Proportion of patients with central line-associated bloodstream infection

    Time frame: Day 90

  2. Non-central line-associated bloodstream infection

    Proportion of patients with non-central line-associated bloodstream infection

    Time frame: Day 90

  3. Catheters with catheter colonization

    Proportion of catheters with catheter colonization

    Time frame: From central venous catheter insertion until 48 hours after catheter removal during the ICU stay (censored at 90 days).

  4. Time to onset of central venous catheter-related infectious complication

    Length of time (in days) before the onset of central venous catheter-related infectious complications

    Time frame: Day 90

  5. ICU length of stay

    Length of ICU stay

    Time frame: Day 90

  6. All-cause ICU mortality

    Number of patients who die from any cause during their ICU stay

    Time frame: Day 90

  7. Cumulative nursing time related to infusion set replacements

    Total nursing time, measured in minutes, required to perform infusion set replacements, per 1000 catheter-days

    Time frame: 1000 days

  8. Cost of materials required for infusion set replacements

    Cost (euros) of materials required for infusion set replacements, per 1000 cathéter days

    Time frame: 1000 days

07

Study locations

1 of 27 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2028, 24 months after the start.

Of 28 non-industry interventional studies with no phase under Catheter-Related Infections, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's planned 24 months is close to that.

Counting every sponsor, half of 31 studies reached it within 22 months; a quarter within 13 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2025
First posted
Sep 19, 2025
StartActual
May 12, 2026
Primary completionEst.
May 2028
CompletionEst.
Dec 2028
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07183592
Responsible party
Sponsor
First posted
Sep 19, 2025
Start date
May 12, 2026
Primary completion
May 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
May 13, 2026

Study contacts

Carole Haubertin
Contact
Carole.Haubertin@chu-angers.fr
+332 41 35 40 82
Aurélie Hautefort
Contact
aurelie.hautefort@chu-angers.fr
+332 41 35 58 99
Carole Haubertin
principal investigator · University Hospital, Angers

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion